Brokerages Set Oruka Therapeutics, Inc. (NASDAQ:ORKA) PT at $48.88

Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) have received an average recommendation of “Moderate Buy” from the ten brokerages that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, eight have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $49.00.

A number of research analysts have recently commented on the company. HC Wainwright dropped their price objective on Oruka Therapeutics from $45.00 to $40.00 and set a “buy” rating on the stock in a report on Monday, October 27th. Barclays initiated coverage on Oruka Therapeutics in a report on Monday, October 13th. They issued an “overweight” rating and a $48.00 price target for the company. Guggenheim began coverage on shares of Oruka Therapeutics in a report on Monday, October 27th. They set a “buy” rating and a $60.00 price objective on the stock. Piper Sandler began coverage on shares of Oruka Therapeutics in a report on Thursday, December 18th. They issued an “overweight” rating and a $75.00 target price for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oruka Therapeutics in a research report on Wednesday, October 8th.

Oruka Therapeutics Price Performance

NASDAQ ORKA opened at $26.40 on Tuesday. The company has a market cap of $1.28 billion, a P/E ratio of -13.89 and a beta of -0.39. The stock has a 50-day moving average of $29.15 and a two-hundred day moving average of $21.21. Oruka Therapeutics has a 1-year low of $5.49 and a 1-year high of $32.64.

Oruka Therapeutics (NASDAQ:ORKA) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.55) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.01. On average, analysts anticipate that Oruka Therapeutics will post -3.41 EPS for the current fiscal year.

Insider Activity

In other news, insider Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $30.61, for a total transaction of $214,270.00. Following the sale, the insider owned 1,518 shares in the company, valued at approximately $46,465.98. The trade was a 82.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 24.69% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Woodline Partners LP lifted its stake in Oruka Therapeutics by 46.9% in the third quarter. Woodline Partners LP now owns 574,330 shares of the company’s stock valued at $11,044,000 after buying an additional 183,426 shares during the last quarter. Polar Capital Holdings Plc increased its holdings in shares of Oruka Therapeutics by 5.9% in the 3rd quarter. Polar Capital Holdings Plc now owns 1,032,307 shares of the company’s stock valued at $19,851,000 after acquiring an additional 57,307 shares during the period. Palo Alto Investors LP purchased a new stake in Oruka Therapeutics in the 3rd quarter valued at $1,154,000. Fairmount Funds Management LLC raised its position in Oruka Therapeutics by 9.9% in the 3rd quarter. Fairmount Funds Management LLC now owns 3,705,262 shares of the company’s stock valued at $71,252,000 after purchasing an additional 333,340 shares during the last quarter. Finally, Commodore Capital LP boosted its stake in Oruka Therapeutics by 23.5% during the 3rd quarter. Commodore Capital LP now owns 1,753,054 shares of the company’s stock worth $33,711,000 after purchasing an additional 333,340 shares during the period. Hedge funds and other institutional investors own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.